NCT05028127

A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

An Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Relative Bioavailability and Tolerability of 160mg Subcutaneous Bimekizumab in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: UCB Celltech · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study to determine the relative bioavailability of bimekizumab in healthy subjects

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	Bimekizumab	Subjects will be receiving bimekizumab at pre-specified time-points.

Timeline

• Start date: 2016-03-04
• Primary completion: 2016-06-17
• Completion: 2016-06-17
• First posted: 2021-08-31
• Last updated: 2021-08-31

Locations

1 site across 1 country: United Kingdom